

# The Role of Vitamin D in the Pathogenesis and Management of Inflammatory Bowel Disease

Randy Adiwinata\*, Marcellus Simadibrata\*\*

\*Faculty of Medicine, Atmajaya Catholic University, Jakarta

\*\*Division of Gastroenterology, Department of Internal Medicine,  
Faculty of Medicine, Universitas Indonesia/Dr. Cipto  
Mangunkusumo General National Hospital, Jakarta

## Corresponding author:

Marcellus Simadibrata. Division of Gastroenterology, Department of Internal Medicine, Cipto Mangunkusumo General National Hospital. Jl. Diponegoro No.71 Jakarta Indonesia. Phone: +62-21-3153957; Facsimile: +62-21-3142454. E-mail: prof.marcellus.s@gmail.com

## ABSTRACT

Vitamin D is widely recognized for its role in maintaining bone metabolism and health. However, recent studies indicated that vitamin D also played important role in regulating the immune system. Patients with inflammatory bowel disease (IBD) are commonly found to be vitamin D deficient; whether it serves as risk factor of IBD or as the consequence of disease activity is still debatable. Growing evidences showed that vitamin D supplementation in IBD patients with the target to achieve normal or optimal serum level might suppress the inflammatory process, reduce disease severity, maintain remission status, and improve quality of life.

**Keywords:** inflammatory bowel disease, vitamin D, immunity

## ABSTRAK

Vitamin D telah lama dikenal dalam mengatur metabolisme dan kesehatan tulang. Akan tetapi, beberapa studi terakhir menunjukkan bahwa vitamin D juga memegang peranan penting dalam pengaturan sistem imun. Pasien dengan inflammatory bowel disease (IBD) sering ditemukan mengalami defisiensi vitamin D, akan tetapi hingga saat ini masih menjadi perdebatan apakah defisiensi vitamin D merupakan faktor resiko ataupun konsekuensi dari aktivitas penyakit IBD. Bukti terbaru menunjukkan bahwa pemberian suplementasi vitamin D pada pasien dengan IBD dengan target kadar serum normal atau optimal, dapat menekan proses inflamasi, menurunkan keparahan penyakit, mempertahankan status remisi, dan meningkatkan kualitas hidup.

**Kata kunci:** inflammatory bowel disease, vitamin D, imunitas

## INTRODUCTION

Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the digestive tract IBD consist of two forms, which are ulcerative colitis (UC) and Crohn's disease (CD).<sup>1</sup> Prevalence data of IBD in Indonesia was mainly derived from hospital based endoscopy unit. The IBD prevalence in Indonesia ranged from 1.16% to 26.5%; while UC was 5.4-26.5% and CD was reported to be between 1-10.2%.<sup>2</sup> The

pathogenesis of IBD is considered as multifactorial, which consists of interactions of genetic, immunity, environmental, and gut microbial factors.<sup>1</sup> Chronic inflammation of the intestinal due to IBD will lead to malabsorption of the nutrients which frequently present as unintentional weight loss and also another serious long term complication, which is colorectal cancer.<sup>3</sup> The mainstay treatment of IBD consist of anti-inflammatory drugs, such as: mesalamine, budesonide,

and newer biologic agents to maintain remission; also, in selected cases surgery may be required.<sup>4</sup>

Vitamin D is a lipid soluble vitamin with long standing history playing important role for bone metabolism and density.<sup>5</sup> Daily requirements of vitamin D intake are mainly derived from diet and photosynthesis which occurs in the skin.<sup>6</sup> Nowadays, vitamin D is recognized for its significant role in regulating immune function, inflammatory response, and possibly in some pathogenesis of autoimmune diseases.<sup>7</sup> Immune regulating effect of vitamin D is achieved by modulating the innate and adaptive immune system.<sup>6</sup>

Vitamin D deficiency is common in IBD patients. Theoretically, vitamin D deficiency may occur in IBD patients who undergo gut resection or as the consequence of malabsorption due to gut inflammation.<sup>8</sup> However, growing evidences indicate vitamin D deficiency may also serve as important environmental risk factor for IBD pathogenesis.<sup>8</sup> Recent studies showed that vitamin D supplementation until achieving normal or optimal level in IBD patients may alter the clinical course of the disease, and proposed to be considered as adjunctive therapy in management of IBD.<sup>9</sup> Therefore, in this review we examined the role of vitamin D and IBD based on latest evidences.

## VITAMIN D SYNTHESIS AND METABOLISM

Vitamin D (calciferol) has two major forms based on their side chain structures, which are: vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol).<sup>10</sup> Vitamin D2 is mainly derived from diet containing plant sterol ergosterol or other fortified food. While, vitamin D3 has two sources which are from diet of animal source foods and synthesis of 7-dehydrocholesterol in the skin by ultraviolet (UV) radiation.<sup>11</sup> The recommended dietary allowances (RDAs) of vitamin D issue by United State Institute of Medicine (IOM) for people aged 1-70 years are 600 IU (15 mcg), and 800 IU (20 mcg) for people aged >70 years.<sup>10</sup> The main source of vitamin D for daily body requirement is from cutaneous photosynthesis; therefore, inadequate exposure to sunlight are linked with vitamin D deficiency.<sup>6</sup>

Vitamin D derived from diet and photosynthesis need to undergo several steps of metabolism and two enzymatic hydroxylations processes to be converted to 1,25-dihydroxy vitamin D ( $1,25(\text{OH})_2\text{D}$ ) which is the biological active vitamin D form and commonly called as calcitriol. First, vitamin D will be transported

in the blood by vitamin D binding protein (DBP) and hydroxylated in the liver by cytochrome P450 vitamin D 25-hydroxylase (CYP2R1, CYP2D11, CYP2D25) to become 25-hydroxyvitamin D ( $25(\text{OH})\text{D}_3$ ). Second hydroxylation will occur in the kidneys by  $25(\text{OH})\text{D}$ -1-OHase (CYP27B1) resulting in calcitriol.<sup>10-12</sup> (Figure 1) Calcitriol ( $1,25(\text{OH})_2\text{D}$ ) acts as a ligand which binds to vitamin D receptor (VDR) and regulates the transcription and expression of targeted vitamin D genes.<sup>13</sup> Previously discovered targeted genes of VDR were mainly resolved around bone and calcium haemostatic metabolisms; recently VDR was also found to be an exerting target to other cells which regulates innate and adaptive immune system.<sup>14</sup> VDR can be found in skin, colon, intestinal enterocytes, pancreatic islets, renal distal tubules, hair follicles, and cells of the immune system.<sup>15,16</sup>




Figure 1. Vitamin D metabolism pathway

## ROLE OF VITAMIN D IN IMMUNITY

One of the beneficial effects of vitamin D supplementation is immune system enhancement. Studies showed that vitamin D deficiency increased the risk of acquired autoimmune disease, tuberculosis, severe infections and mortality in critically ill patients.<sup>17-19</sup> Immunomodulator effect of vitamin D is linked to the finding of VDR expressed by many immune cells, such as T & B cell lymphocytes, monocytes, and antigen-presenting-cells; therefore it can be concluded that vitamin D may modulate innate and adaptive immune system.<sup>7</sup>

Vitamin D enhances the innate immune system through pathogen sensing mechanism by monocyte CYP27B1 (a vitamin D-activating enzyme), increase monocyte proliferation, and antimicrobial protein (cathelicidin), IL-1, and IL-10 production. After pathogens are phagocytosed, CYP27B1 and VDR inside the monocyte will be activated, resulting in the utilization of 25(OH)D in the blood and alteration to 1,25 (OH)<sub>2</sub>D locally (intracrine process).<sup>20-22</sup> Calcitriol will bind to endogenous monocyte VDR and induce the production of cathelicidin which in turn augment the eradication of pathogens inside the monocyte.<sup>20</sup> The immunomodulatory effect of vitamin D toward dendritic cell are related with the immune tolerance and suppression mechanism which interplay with adaptive immune system. Therefore, it is hypothesized that it may help in autoimmune disease.<sup>21,22</sup> The binding of 1,25 (OH)<sub>2</sub>D with dendritic cell VDR induce suppression of the dendritic cell maturation, antigen presentation, IL-12 production, and increase production of IL-10. IL-12 suppression will lead to decreased production of T helper 1 T-cells and increased production of Thelper 2. Meanwhile IL-10 is regarded as immunosuppressive cytokines.<sup>22</sup>

Vitamin D may exert immunosuppressive or tolerogenic effect in adaptive immune system by inhibiting through inhibition of T cell proliferation, B cell differentiation and immunoglobulin secretion, Th17 suppression, and enhancing T regulatory (Treg) production.<sup>7,23</sup> Suppression of T cell will inhibit pro-inflammatory cytokine production. Treg regulates excessive inflammation process which may help in autoimmune disease.<sup>20</sup> Th17 produced IL-17, which in many autoimmune diseases, such as IBD, systemic lupus erythematosus and others are found to be elevated.<sup>24</sup>

#### **VITAMIN D DEFICIENCY STATUS: RISK FACTORS AND MODULATING FACTORS OF DISEASE ACTIVITY IN IBD PATIENTS**

Many studies found that patients with IBD had low level of Vitamin D; therefore, Vitamin D status was considered linked as one of the environmental risk factors for IBD.<sup>25</sup> However, there were some points which need to be considered from the result of those studies: (1) Whether Vitamin D deficiency preceded the occurrence of IBD or Vitamin D deficiency was the implication of clinical course of IBD; (2) Use of different cut off levels of 2,5(OH)D to determine the adequacy level of vitamin D status; (3) Varied

measurement of 2,5(OH)D level between studies which might be affected by duration of sun exposures (winter or summer) and geographical location.<sup>10,26,27,28</sup>

There are two guidelines which are used to define the cut-off level for the vitamin D adequacy status. The first one is the guideline by IOM in 2011, defining vitamin D deficiency as 2,5(OH)D level < 30 nmol/L (12 ng/mL), inadequate vitamin D as 30-50 nmol/L (12-20 ng/mL), and sufficient as 2,5(OH)D level above 50 nmol/L (20 ng/mL).<sup>10</sup> Another guideline published by the Endocrine Society in 2011 defines vitamin D deficiency as 2,5(OH)D level below 50 nmol/L (20 ng/mL) and vitamin D insufficiency as 52.5-72.5 nmol/L (21-29 ng/mL).<sup>27</sup>

Studies found that the prevalence of vitamin D deficiency in IBD patients ranged from 8% up to 95%.<sup>8</sup> Recent observational multi-centre study in Norway found 49% of total patients had 2,5(OH)D level below 50 nmol/L. Vitamin D deficiency was more common in CD compared to ulcerative colitis (UC) patients (53% vs. 44%). This study also attained that vitamin D deficiency was related with severity of IBD, which was described as higher relapse rate and higher inflammatory level.<sup>29</sup> A cross sectional study by Raftery et al showed that vitamin D level were inversely correlated with faecal calprotectin level, which was regarded as a marker of intestinal inflammation in IBD.<sup>30</sup> Torki et al found that up to 39% of IBD patients in Iran were having 2,5(OH)D level < 50 nmol/L; also, low vitamin D level was independently associated with status of disease activity.<sup>31</sup> Retrospective cohort study by Ulitsky et al which included 504 IBD patients (403 CD and 101 UC) and had more than 10 years mean disease duration, showed that 49.8% of the patients were vitamin D deficient and 10.9% had severe vitamin D deficiency. This study also reported that vitamin D was associated with lower quality of life and increased disease activity in CD.<sup>32</sup> A cohort study consisted of 220 IBD patients found that higher vitamin D level (50-59 ng/ml) were associated with better quality of life (assessed with short IBD questionnaire).<sup>33</sup> Recently published study revealed that normal vitamin D level status in IBD patients managed with anti-TNF $\alpha$  medications had more than two times higher odds of remission compared to low level vitamin D IBD patients.<sup>34</sup> Prospective study by Gubatan et al exhibited that among 70 patients with UC, lower vitamin D level was found in relapse group (29.5 ng/mL vs. 50.3 ng/mL,  $p = 0.001$ ). Serum vitamin D level of 35 ng/ml or less had predictive role for increased risk of clinical relapse with sensitivity of 70% and specificity of

74%.<sup>35</sup> A five year longitudinal study consisting of 965 IBD patients (61.9% CD and 38.1% UC) found that almost 30% of the patients were having low level of vitamin D. After 5 years of observation, IBD patients with low level vitamin D were found to have higher morbidity, number of hospitalization and surgery, need of steroids, higher disease activity score, and lower quality of life.<sup>36</sup> A retrospective multi-centre study in USA concluded that IBD patients with vitamin D level < 20 ng/ml were twice more prone to acquire *Clostridium difficile* infection.<sup>37</sup> Two meta-analyses published in 2015, found that IBD patients had lower vitamin D serum level.<sup>38,39</sup> Meta-analysis by Lu et al concluded that there were more patients with active CD had low vitamin D level.<sup>39</sup> McCarthy et al found that there was vitamin D level variation among CD patients related with season; in winter, vitamin D level tend to be lower.<sup>28</sup>

While data show the prevalence of vitamin D deficiency in IBD patients, it is difficult to determine whether vitamin D deficiency was risk factor of developing IBD or was the consequence of IBD; as most of the studies measured the vitamin D level on established IBD patients. Several causes of low vitamin D level in IBD patients are decreased sunlight exposure, decreased oral intake of vitamin D, and also reduced ability to absorb vitamin D.<sup>32</sup> Farraye et al showed that there was 30% reduction of vitamin D2 absorption capability in CD patients.<sup>40</sup> Furthermore, ileum terminale resection performed in IBD patients might further impair the absorption of vitamin D.<sup>32</sup>

#### **PATHOGENESIS OF IBD IN RELATION TO GENETIC AND VDR GENES POLYMORPHISM**

The pathogenesis of IBD remains elusive. Current theory highlights the interaction between environment, genetic predisposition, immune system, and mucosal ecology.<sup>41</sup> Nucleotide-binding oligomerization domain 2 (NOD2) gene mutation was found to be responsible in the pathogenesis of CD. NOD2 acts in the regulation of mucosal intestinal barrier by recognition of peptidoglycan produced by bacteria, induction of protective inflammatory response, production of antimicrobial peptide defensin beta2 (DEFB2/HBD2), and autophagy. However, the mutation of NOD2 gene will lead to loss of peptidoglycan sensing and lack of protective inflammatory response, which in turn will result in dysbiosis, barrier dysfunction, and chronic inflammation.<sup>41,42</sup> Recent study found that NOD2 was among the targeted gene of 1,25 (OH)<sub>2</sub>D signaling;

stimulation of NOD2 by 1,25 (OH)<sub>2</sub>D will lead to enhanced autophagy.<sup>43</sup> Vitamin D deficiency may impair the stimulation of NOD2, which may lead to impaired mucosal barrier.<sup>44</sup>

VDR gene polymorphisms had been studied and implicated to increase the risk of suffering from IBD; however the studies generated mixed and inconclusive result. This study used the same location of the VDR gene with IBD-associated genes, the chromosome 12.<sup>41</sup> VDR gene polymorphism may affect the expression and transcription process, which may play influential role in inflammation process.<sup>45</sup> Some of the commonly studied VDR polymorphisms associated with IBD are TaqI, BsmI, FokI, and ApaI.<sup>41,46</sup>

#### **VITAMIN D SUPPLEMENTATION AS ADJUNCTIVE THERAPY IN IBD**

Based on the physiology of vitamin D immunomodulatory effects described above, several studies had been conducted to assess the benefit of vitamin D supplementation in IBD management. In vitro study showed that the inflamed and non-inflamed colon of the UC patients that were cultured with 1,25(OH)<sub>2</sub>D<sub>3</sub> had decreased claudin-1, claudin-2 protein level, IL-13 and IL-6, and increased claudin-4 and claudin-7; therefore, it could be concluded that vitamin D might modulate the cytokine inflammation synthesis and regulate the tight junction protein expression.<sup>47</sup> Elimrani et al found that vitamin D supplemented mice had lower colitis activity index, histological inflammation score, weight loss, and IL-6 level and higher survival rates compared to vitamin D deficient mice.<sup>48</sup> Vitamin D may inhibit the excessive apoptosis of intestinal epithelial cells due to chronic inflammation in IBD patients. Mice with 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced-colitis treated with paricalcitol were having lower expression of caspase-3 and p53 upregulated modulator of apoptosis (PUMA), but not the p53 expression; which was regarded as the important protein in inducing apoptosis pathway.<sup>49</sup> Study in chronic colitis mice showed that vitamin D supplementation might induce VDR resulting in the inhibition of TGF-β1/Smad3 pathway in colonic subepithelial myofibroblasts (SEMF) which in turn prevent intestinal fibrosis.<sup>50</sup>

A double-blind randomized controlled trial conducted by Sharifi et al investigated the effect of high dosage (300,000 IU) of vitamin D3 supplementation administered once through intramuscular injection on systemic inflammation marker of IBD (erythrocyte

sedimentation rates [ESR] and C-reactive protein [CRP] level) and cathelicidin (LL37) gene expression among 90 UC patients on remission. Expression of LL37 gene will lead to increased production of human

cathelicidin antimicrobial protein 18 (hCAP18). Baseline of vitamin D levels between the intervention and placebo group were not significantly different. After intervention, ESR and Hs-CRP level were decreased

**Table 1. Human studies regarding vitamin D supplementation in inflammatory bowel disease (IBD) patients.**

| Study                       | Study design                                     | Sample                                      | Intervention                                                                                                                                                                                                                                                                            | Result                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------------|--------------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Miheller et al, 2009        | Prospective cohort study                         | 37 inactive CD patients                     | Group A: treated with 1,25 (OH) <sub>2</sub> D [active form of vit D]<br>Group B: treated with plain vitamin D<br>For 6 weeks, 3 and 12 months                                                                                                                                          | Significant decrease of CDAI and CRP level in Group A at the 6 weeks.                                                                                                                                                                                                                                                                                   |
| Jørgensen et al, 2010       | Randomized double blind placebo-controlled trial | 94 CD patients                              | Group A: treated with oral 1200 IU vitamin D3 daily (46 patients)<br>Group B: given placebo (48 patients)<br>Intervention period: 12 months                                                                                                                                             | Significant increase of serum 25OHD level seen after 3 months supplementation in Group A and lower relapse rate in Group A compared to Group B (13% vs. 29%; P=0.06)                                                                                                                                                                                    |
| Yang et al, 2013            | Open-labeled prospective clinical study          | 18 mild-moderate CD patients                | 1,000 IU Vitamin D3 were given daily for two weeks, and then the dose was escalated to achieve 40 ng/ml 25 (OH)D3 serum concentration or maximum 5,000 IU daily.<br>Intervention period: 24 weeks                                                                                       | Two weeks of 1,000 IU vitamin D3 daily was not adequate to raise the vitamin D serum level.<br>78% of patients need 5,000 IU daily to achieve the target vitamin D level.<br>Reduced CDAI score (p<0.0001) and increased QoL (p=0.0004) were found after 24 weeks vit D supplementation; however, no significant changes were found in cytokines level. |
| Ananthakrishnan et al, 2013 | Retrospective Cohort                             | 3217 IBD patients (55% CD)                  | None                                                                                                                                                                                                                                                                                    | Serum level of 25 (OH)D <20 ng/ml was associated with increased risk of surgery (OR:1.76; 95% CI, 1.24-2.51) and IBD related hospitalization (OR 2.07; 95% CI, 1.59-2.68) compared to patients with >30 ng/ml 25 (OH)D.                                                                                                                                 |
| Raftery et al, 2015         | Double-blind randomized placebo-controlled study | 27 CD patients in remission                 | Group A: 13 patients supplemented with 2,000 IU vitamin D3<br>Group B: 14 patients given placebo<br>Intervention period: 3 months                                                                                                                                                       | Normalization of 25 (OH)D level decreased the risk of surgery (OR 0.56; 95% CI: 0.32-0.98)<br>Patients with serum level of 25 (OH)D ≥75 nmol/L were found to have higher QoL (p=0.037), higher LL-37 concentrations (p<0.001), lower CRP (p=0.019), and lower insignificant CDAI scores (p=0.082).                                                      |
| Dadaei et al, 2015          | RCT, analysis with intention to treat            | 108 IBD patients with Serum 25OHD <30 ng/ml | Group A: 53 patients were treated with 50,000 IU vitamin D3<br>Group B: 55 patients served as control<br>Intervention period: 12 weeks                                                                                                                                                  | Insignificant decrease of TNF-α were found in Group A (p=0.07, CI 95%:-0.45 to 8.14)<br>TNF-α level were significantly correlated with clinical disease activity index before and after intervention.                                                                                                                                                   |
| Sharifi et al, 2016         | RCT, analysis with intention to treat            | 90 UC patients on remission                 | Group A: 46 patients were treated with 300,000 IU intramuscular vitamin D once.<br>Group B: 44 patients given placebo                                                                                                                                                                   | Significant decrease of Hs-CRP level (p = 0.023), ESR level (p < 0.001), and higher cathelicidin level which reflected by hCAP18 gene expression (p < 0.001) in group treated with vitamin D.                                                                                                                                                           |
| Kabbani et al, 2016         | Five year longitudinal study                     | 965 IBD patients (61.9% CD & 52.3% female)  | Taken from longitudinal IBD natural history registry.<br>Routine testing of serum vitamin D level were done.<br>Vitamin D supplementation was given to patients with status of deficiency or insufficiency. The protocol: 50,000 IU vitamin D weekly or biweekly for at least 12 weeks. | Low vitamin D level was associated with more treatment, hospital admissions, and surgery (p<0.05); also higher pain, disease activity scores, and lower QoL (P,0.05).<br>Patients with vitamin D supplementation were associated with reduced utilization of healthcare.                                                                                |
| Narula et al, 2017          | Randomized double blind placebo-controlled trial | 34 CD patients in remission                 | Group A: 18 patients received 10,000 IU vitamin D3 daily,<br>Group B: 16 patients received 1000 IU vitamin D3 daily<br>Intervention period: 12 months                                                                                                                                   | Intention to treat analysis result: no significant different in term of clinical relapse rate between Group A and B (33.3%vs. 68.8%, p=0.0844)<br>Per-protocol analysis: Clinical relapse rate were lower in high dose vitamin D supplemented group compared to low dose group (0% vs. 37.5%; p=0.049)                                                  |

significantly and there was significant increase of LL37 gene expression among UC patients in vitamin D supplemented group.<sup>51</sup> This finding was also supported by the study conducted by Raftery et al, that among CD patients in remission who were supplemented with vitamin D 2000 IU/day for 3 months were associated with increased LL37 concentration and maintenance of intestinal permeability. Among those UC patients, those with 25(OH)D level  $\geq 75$  nmol/L were associated with reduced CRP level, higher quality of life and LL37 concentration.<sup>52</sup> Jorgensen et al found insignificant lower relapse rate among vitamin D (1200 IU) supplemented CD patients after three months of intervention compared to placebo group (13% vs. 29%,  $p = 0.06$ ).<sup>53</sup> A small cohort study consisting of 18 CD patients with mild-moderate degree (150-400 Crohn's disease activity index [CDAI]) were supplemented with oral vitamin D3 1000 IU daily and were up titrated until they achieved 25(OH)D3 serum level of 40 ng/ml or maximum dose of 5000 IU daily. The result was vitamin D supplementation significantly reduced CDAI index and improved the quality of life.<sup>54</sup> Ananthakrishnan et al who conducted retrospective analysis consisting of 3,217 IBD American patients (55% were CD), found that normalization of serum vitamin D level would lower half of the risk for surgery among CD patients.<sup>55</sup> Mihaller compared the effectivity of the active form of vitamin D (1,25(OH)<sub>2</sub>D) with plain form of vitamin D (25 (OH)D) supplementation in CD patients. After 6 weeks of supplementation, there were significant reduction of CDAI, CRP, and bone turnover in active vitamin D form group.<sup>56</sup> Recently published study in 2017 reported that high dose vitamin D3 supplementation (10,000 IU) daily was associated with significant improvement of 25 (OH) D level; however, the rates of clinical relapse were similar to the group who were supplemented with low dose vitamin D3 (1000 IU) daily (68.8% vs. 33.3%,  $p = 0.084$ ).<sup>57</sup> Treatment of low vitamin D level before initiating anti-TNF medication are needed, because there is significant association with positivity for antinuclear antibodies (ANA) which is linked to higher failure rates and adverse event of anti-TNF therapy.<sup>58</sup> The target of vitamin D level which exert optimal immunomodulatory effect that may benefit IBD patients, has not been formally established. A literature review by Raftery et al suggested that achieving serum level vitamin D of  $\geq 75$  nmol/L might be needed to benefit CD patients.<sup>59</sup> Human studies regarding the use of vitamin D supplementation for IBD management are summarized in Table 1.

## CONCLUSION

Currently the role of vitamin in IBD pathogenesis and management has been recognized, especially due to the nature of immunomodulatory effect of vitamin D. Most studies found higher prevalence of low vitamin D level in IBD patients; however it remained difficult to determine whether vitamin D deficiency is the risk factor of developing IBD or the consequence of IBD activity course. Recent human studies indicate that vitamin D supplementation especially in vitamin D deficiency IBD patient may benefit in term of alleviating disease activity, maintaining clinical remission, and improving quality of life. Therefore, we suggest vitamin D level assessment in IBD patients. Local data regarding the prevalence of vitamin D deficiency, benefit of vitamin D supplementation, and optimum vitamin D level among Indonesian IBD patients are needed to make specific recommendation.

## REFERENCES

1. Zhang YZ, Li YY. Inflammatory bowel disease: Pathogenesis. *World J Gastroenterol*: WJG 2014;20:91-9.
2. Indonesia Society of Gastroenterology (ISG). National Consensus of the Management of Inflammatory Bowel Disease in Indonesia. Jakarta: ISG; 2011.
3. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. *Frontiers in Immunology* 2012;3.
4. Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. *World Journal of Gastrointestinal Pharmacology and Therapeutics* 2016;7:5-20.
5. Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. *Best practice & research Clinical endocrinology & metabolism* 2011;25:585-91.
6. Nair R, Maseeh A. Vitamin D: The "sunshine" vitamin. *Journal of Pharmacology & Pharmacotherapeutics* 2012;3:118-26.
7. Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and Immune Function. *Nutrients* 2013;5:2502-21.
8. Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. *Alimentary pharmacology & therapeutics* 2014;39:125-36.
9. Ardesia M, Ferlazzo G, Fries W. Vitamin D and Inflammatory Bowel Disease. *BioMed Research International*. 2015;2015.
10. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D [Internet]. Washington: National Academies Press; 2011 [serial online] [cited 2017 January 8]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK56061/#ch3.s5>.
11. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. *Chemistry & biology* 2014;21:319-29.
12. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: Metabolism. *Endocrinology and metabolism clinics of North America* 2010;39:243-53.

13. Ying HQ, Sun HL, He BS, Pan YQ, Wang F, Deng QW, et al. Circulating vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D and risk of colorectal cancer. *Scientific Reports* 2015;5:7956.
14. Pike JW, Meyer MB. The Vitamin D Receptor: new paradigms for the regulation of gene expression by 1,25-Dihydroxyvitamin D(3). *Endocrinology and metabolism clinics of North America* 2010;39:255-69.
15. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? *Archives of biochemistry and biophysics* 2012;523:123-33.
16. Haussler MR, Haussler CA, Bartik L, Whitfield GK, Hsieh JC, Slater S, Jurutka PW, et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. *Nutrition reviews*. 2008;66:S98-112.
17. Hewison M. Vitamin D and immune function: an overview. *The Proceedings of the Nutrition Society* 2012;71:50-61.
18. de Haan K, Groeneveld ABJ, de Geus HRH, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Critical Care* 2014;18.
19. Gibney KB, MacGregor L, Leder K, Toressi J, Marshall C, Ebeling PR, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from Sub-Saharan Africa. *Clinical Infectious Diseases* 2008;46:443-6.
20. Hewison M. An update on vitamin D and human immunity. *Clinical endocrinology* 2012;76:315-25.
21. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. *Nature reviews Immunology* 2008;8:685-98.
22. Lagishetty V, Liu NQ, Hewison M. Vitamin D metabolism and innate immunity. *Molecular and cellular endocrinology* 2011;347:97-105.
23. Aranow C. Vitamin D and the Immune System. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*. 2011;59:881-6.
24. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. *Archivum Immunologiae et Therapiae Experimentalis* 2015;63:435-49.
25. Suibhne TN, Cox G, Healy M, O'Morain C, O'Sullivan M. Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. *Journal of Crohn's & colitis* 2012;6:182-8.
26. Ananthakrishnan AN. Vitamin D and Inflammatory Bowel Disease. *Gastroenterology & Hepatology* 2016;12:513-5.
27. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism* 2011;96:1911-30.
28. McCarthy D, Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. *Alimentary pharmacology & therapeutics* 2005;21:1073-83.
29. Frigstad SO, Hoivik M, Jahnsen J. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. *Scandinavian journal of gastroenterology* 2017;52:100-6.
30. Raftery T, Merrick M, Healy M, Mahmud N, O' Morain C, Smith S, et al. Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn's Disease in Clinical Remission. *Digestive diseases and sciences* 2015;60:2427-35.
31. Torki M, Gholamrezaei A, Mirbagher L, Danesh M, Kheiri S, Emami MH. Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. *Digestive diseases and sciences* 2015;60:3085-91.
32. Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadornova Y, Binion DG, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. *JPEN Journal of parenteral and enteral nutrition* 2011;35:308-16.
33. Hlavaty T, Krajcovicova A, Koller T, Toth J, Nevidanska N, Huorka M, et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. *World journal of gastroenterology* 2014;20:15787-96.
34. Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases. *Alimentary pharmacology & therapeutics*. 2017.
35. Gubatan J, Mitsunashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2017;15:240-6.e1.
36. Kabbani TA, Koutroubakis IE, Schoen RE, Ramos RC, Shah N, Swoger J, et al. Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. *The American journal of gastroenterology* 2016;111:712-9.
37. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, et al. Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases. *Alimentary pharmacology & therapeutics* 2014;39:1136-42.
38. Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association between inflammatory bowel disease and vitamin D deficiency: A systematic review and meta-analysis. *Inflammatory bowel diseases* 2015;21:2708-17.
39. Lu C, Yang J, Yu W, Li D, Xiang Z, Lin Y, et al. Association between 25(OH)D level, ultraviolet exposure, geographical location, and inflammatory bowel disease activity: a systematic review and meta-analysis. *PloS one* 2015;10:e0132036.
40. Farraye FA, Nimitphong H, Stucchi A, Dendrinios K, Boulanger AB, Vijeswarapu A, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. *Inflammatory bowel diseases* 2011;17:2116-21.
41. Lu R, Wu S, Xia Y, Sun J. The vitamin D receptor, inflammatory bowel diseases, and colon cancer. *Current colorectal cancer reports* 2012;8:57-65.
42. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of inflammation in health and disease. *Nature reviews Immunology* 2014;14:9-23.
43. Dionne S, Calderon MR, White JH, Memari B, Elimrani I, Adelson B, et al. Differential effect of vitamin D on NOD2- and TLR-induced cytokines in Crohn's disease. *Mucosal Immunol* 2014;7:1405-15.
44. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, et al. Direct and indirect induction by

- 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. The Journal of biological chemistry 2010;285:2227-31.
45. Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World journal of gastroenterology 2016;22:933-48.
46. Pei FH, Wang YJ, Gao SL, Liu BR, Du YJ, Liu W, et al. Vitamin D receptor gene polymorphism and ulcerative colitis susceptibility in Han Chinese. Journal of digestive diseases 2011;12:90-8.
47. Stio M, Retico L, Annese V, Bonanomi AG. Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scandinavian journal of gastroenterology 2016;51:1193-9.
48. Elimrani I, Koenekoop J, Dionne S, Marcil V, Delvin E, Levy E, et al. Vitamin D Reduces Colitis- and Inflammation-Associated Colorectal Cancer in Mice Independent of NOD2. Nutrition and cancer 2017;69:276-88.
49. Zhu T, Liu TJ, Shi YY, Zhao Q. Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. International journal of molecular medicine 2015;35:1213-8.
50. Tao Q, Wang B, Zheng Y, Jiang X, Pan Z, Ren J. Vitamin D prevents the intestinal fibrosis via induction of vitamin D receptor and inhibition of transforming growth factor-beta1/Smad3 pathway. Digestive diseases and sciences 2015;60:868-75.
51. Sharifi A, Hosseinzadeh-Attar MJ, Vahedi H, Nedjat S. A Randomized Controlled Trial on the Effect of Vitamin D3 on Inflammation and Cathelicidin Gene Expression in Ulcerative Colitis Patients. Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association 2016;22:316-23.
52. Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study. United European gastroenterology journal 2015;3:294-302.
53. Jorgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Alimentary pharmacology & therapeutics 2010;32:377-83.
54. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn's patients. Clinical and translational gastroenterology 2013;4:e33.
55. Ananthakrishnan AN, Cagan A, Gainer VS, Cai T, Cheng SC, Savova G, et al. Normalization of Plasma 25-hydroxy Vitamin D is Associated with Reduced Risk of Surgery in Crohn's Disease. Inflammatory bowel diseases 2013;19:1921-7.
56. Miheller P, Muzes G, Hritz I, Lakatos G, Peregú I, Lakatos PI, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflammatory bowel diseases 2009;15:1656-62.
57. Narula N, Cooray M, Anglin R, Muqtadir Z, Narula A, Marshall JK. Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study. Digestive diseases and sciences 2017;62:448-55.
58. Santos-Antunes J, Nunes AC, Lopes S, Macedo G. The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study. Inflammatory bowel diseases 2016;22:1101-6.
59. Raftery T, O'Sullivan M. Optimal vitamin D levels in Crohn's disease: a review. The Proceedings of the Nutrition Society 2015;74:56-66.